Cord Blood America CEO Matthew Schissler Interviewed On 2011 Financial Performance, Stock Price, 2012 Strategies
LAS VEGAS, Dec. 8, 2011 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that co-founder and CEO Matthew Schissler was interviewed by analyst Francis Gaskins about the Company's 2011 financial performance.
The entire interview is available at: http://gaskinsco.com/cbai-12-6-11-b.mp3
Mr. Schissler said in the interview that the Company's financial performance is significantly better compared to several years ago. "We are confident on a go-forward basis that if we concentrate on the fundamentals, the stock price will follow."
"We were focused in 2011 on increasing the gross profit, diversifying revenues, reducing expenses, streamlining operations. These are the fundamentals and our trends are in the right direction. We are moving toward becoming cash-flow positive," Mr. Schissler said. CBAI's CEO said sales remain strong in the fourth quarter of 2011.
"Acquisitions are still possible in 2012 and we are keeping a close watch on the letters of intent we signed," Cord Blood America's co-founder said. But he said that the economy for micro cap stocks would have to improve for the Company to make a major acquisition at this time. "We are focused on continuing to improve the Company's financial performance, to bolster our pure organic growth, and to ensure that the acquisitions we made continue to benefit Cord Blood America's investors," Mr. Schissler concluded.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
E & E Communications
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
SOURCE Cord Blood America, Inc.
More by this Source
Cord Blood America Announces 2013 Third Quarter Financial Results
Nov 14, 2013, 08:30 ET
Cord Blood America Announces 2013 Second Quarter Financial Results
Aug 15, 2013, 08:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.